Information Provided By: 
Fly News Breaks for October 25, 2016
FPRX
Oct 25, 2016 | 05:53 EDT
Citi analyst Robyn Karnauskas started Five Prime Therapeutics with a Buy rating and $65 price target. The company has "multiple shots" on goal in various cancers, Karnauskas tells investors in a research note. She believes investors will assign higher value to the Cabiralizumab program once combo data with Opdivo is seen in 2017. The analyst sees fair value for Five Prime shares in the $65-$80 range.
News For FPRX From the Last 2 Days
There are no results for your query FPRX
